Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1988 Jul;26(1):53–59. doi: 10.1111/j.1365-2125.1988.tb03363.x

A comparison of bisoprolol and atenolol in the treatment of mild to moderate hypertension.

R Lewis 1, D Maclean 1, C Ioannides 1, A Johnston 1, D G McDevitt 1
PMCID: PMC1386499  PMID: 2904825

Abstract

1. Fourteen patients (mean age 56.0, range 37-61 years; eight females) with mild essential hypertension (DBP greater than 90 mm Hg on placebo) completed a randomised, double-blind placebo controlled crossover study comparing the hypotensive effects of bisoprolol (10-20 mg) and atenolol (50-100 mg) each taken once daily. 2. Bisoprolol had a significantly greater antihypertensive effect than atenolol, reducing sitting blood pressures by 15.9 mm Hg (diastolic) and 21.9 mm Hg (systolic) compared with placebo. Corresponding figures for atenolol were 10.7 and 5.7 mm Hg respectively. Bisoprolol reduced standing blood pressures by 15.9 mm Hg (diastolic) and 22.8 mm Hg (systolic) compared with 7.3 and 8.6 mm Hg respectively for atenolol. 3. Examination of the pharmacokinetic data showed that bisoprolol had a median elimination half-life of 11.2 h during chronic dosing, compared with 6.4 h for atenolol. For bisoprolol, the median clearance fell from 264 ml min-1 after a single dose to 212 ml min-1 during chronic dosing, although clinically significant accumulation would not be expected during chronic administration. 4. Overall, the results suggest that bisoprolol may be a more effective antihypertensive agent than atenolol but larger studies are necessary to confirm these findings.

Full text

PDF
53

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brown H. C., Carruthers S. G., Johnston G. D., Kelly J. G., McAinsh J., McDevitt D. G., Shanks R. G. Clinical pharmacologic observations on atenolol, a beta-adrenoceptor blocker. Clin Pharmacol Ther. 1976 Nov;20(5):524–534. doi: 10.1002/cpt1976205524. [DOI] [PubMed] [Google Scholar]
  2. Bühring K. U., Garbe A. Determination of the new beta-blocker bisoprolol and of metoprolol, atenolol and propranolol in plasma and urine by high-performance liquid chromatography. J Chromatogr. 1986 Oct 31;382:215–224. doi: 10.1016/s0378-4347(00)83519-7. [DOI] [PubMed] [Google Scholar]
  3. Cooke E. D., Maltz M. B., Smith R. E., Bowcock S. A., Watkins C. J., Camm A. J. Peripheral vascular effects of beta-adrenoceptor blockade: comparison of two agents. Br J Clin Pharmacol. 1987 Sep;24(3):359–366. doi: 10.1111/j.1365-2125.1987.tb03181.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Davidson C., Thadani U., Singleton W., Taylor S. H. Comparison of antihypertensive activity of beta-blocking drugs during chronic treatment. Br Med J. 1976 Jul 3;2(6026):7–9. doi: 10.1136/bmj.2.6026.7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Deacon S. P., Barnett D. Comparison of atenolol and propranolol during insulin-induced hypoglycaemia. Br Med J. 1976 Jul 31;2(6030):272–273. doi: 10.1136/bmj.2.6030.272. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fitzgerald J. D., Ruffin R., Smedstad K. G., Roberts R., McAinsh J. Studies on the pharmacokinetics and pharmacodynamics of atenolol in man. Eur J Clin Pharmacol. 1978 May 17;13(2):81–89. doi: 10.1007/BF00609750. [DOI] [PubMed] [Google Scholar]
  7. Jeffers T. A., Webster J., Petrie J. C., Barker N. P. Atenolol once-daily in hypertension. Br J Clin Pharmacol. 1977 Oct;4(5):523–527. doi: 10.1111/j.1365-2125.1977.tb00780.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Johnston A., Woollard R. C. STRIPE: an interactive computer program for the analysis of drug pharmacokinetics. J Pharmacol Methods. 1983 May;9(3):193–199. doi: 10.1016/0160-5402(83)90038-4. [DOI] [PubMed] [Google Scholar]
  9. Kirch W., Köhler H., Mutschler E., Schäfer M. Pharmacokinetics of atenolol in relation to renal function. Eur J Clin Pharmacol. 1981 Jan;19(1):65–71. doi: 10.1007/BF00558387. [DOI] [PubMed] [Google Scholar]
  10. Klockow M., Greiner H. E., Haase A., Schmitges C. J., Seyfried C. Studies on the receptor profile of bisoprolol. Arzneimittelforschung. 1986 Feb;36(2):197–200. [PubMed] [Google Scholar]
  11. Leopold G., Ungethüm W., Pabst J., Simane Z., Bühring K. U., Wiemann H. Pharmacodynamic profile of bisoprolol, a new beta 1-selective adrenoceptor antagonist. Br J Clin Pharmacol. 1986 Sep;22(3):293–300. doi: 10.1111/j.1365-2125.1986.tb02890.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Yamaoka K., Nakagawa T., Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm. 1978 Apr;6(2):165–175. doi: 10.1007/BF01117450. [DOI] [PubMed] [Google Scholar]
  13. Yee Y. G., Rubin P., Blaschke T. F. Atenolol determination by high-performance liquid chromatography and fluorescence detection. J Chromatogr. 1979 Apr 1;171:357–362. doi: 10.1016/s0021-9673(01)95315-4. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES